N, funded
and supported by the National Institutes of Health (NIH), is the largest
worldwide clinical trials program devoted to the development and testing of
HIV/AIDS vaccines. Preclinical work enabling development of the clinical
evaluation of GeoVax DNA and MVA vaccines was also funded and supported by
the NIH National Institute of Allergy and Infectious Diseases (NIAID).
GeoVax DNA & MVA Genetically Engineered HIV/AIDS vaccines:
-- DNA vaccine "primes" immune responses & MVA vaccine "boosts" immune
responses against the AIDS virus
-- Both express over 50% of AIDS virus components in vaccine recipients --
Can not cause AIDS
-- Protected 22 of 23 (96%) non-human primates against AIDS for over 31/2
years
-- Are manufactured & tested under GMP/GLP -- EMEA (EU) and FDA [USA]
guidelines
-- Satisfactorily completed 2 earlier HIV/AIDS vaccine Phase 1 human
trials. Currently have 3 ongoing Phase 1 Human Trials -- 1 was
initiated in 2006, 2 in summer 2007
-- Have been demonstrated safe to date in human trials
-- Demonstrate positive anti-HIV immune responses in majority of human
vaccine recipients
-- Are in planning for mid 2008 Phase 2 trials in based on positive
results in Phase 1 trials
Safe Harbor Statement: All statements in this news release, not
statements of historical fact, are forward-looking statements. These
statements are based on expectations and assumptions on the date of this
press release and are subject to numerous risks and uncertainties which
could cause actual results to differ materially from those described in the
forward-looking statements. Risks and uncertainties include, but are not
limited to, whether: GeoVax can develop and manufacture these vaccines with
the desired characteristics in a timely manner, GeoVax's vaccines will be
safe for human use, GeoVax's vaccines will effectively prevent AIDS in
humans,
'/>"/>
SOURCE GeoVax Labs, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update2.
U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program3.
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line4.
China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products5.
VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives6.
Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors7.
New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform8.
Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder9.
Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers10.
AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment11.
SAFC Hitech(TM) Plans Further Expansion Into Asia